The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Zanier, Katia ^a   Stutz, Christina ^b   Kintscher, Susanne ^b   Reinz, Eileen ^b   Sehr, Peter ^c   Bulkescher, Julia ^b   Hoppe Seyler, Karin ^b   Travé, Gilles ^a   Hoppe Seyler, Felix ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

E6APPEP; PEP11; PROTEIN E6; PROTEIN INHIBITOR; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E6AP; UNCLASSIFIED DRUG; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PEPTIDE; REPRESSOR PROTEIN; UBE3A PROTEIN, HUMAN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; IN VITRO STUDY; MOLECULAR DOCKING; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; TWO HYBRID SYSTEM; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HELA CELL LINE; METABOLISM; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HELA CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; ONCOGENE PROTEINS, VIRAL; PEPTIDES; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; UBIQUITIN-PROTEIN LIGASES;

EID: 84911439308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112514     Document Type: Article

References (32)

1. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006) Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3: S3/26-34.
2. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
3. McLaughlin-Drubin ME, Munger K (2009) Oncogenic activities of human papillomaviruses. Virus Res 143: 195-208.
4. Hoppe-Seyler F, Hoppe-Seyler K (2011) Emerging topics in human tumor virology. Int J Cancer 129: 1289-1299.
5. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937.
6. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
7. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F (2000) Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A 97: 6693-6697.
8. Goodwin EC, DiMaio D (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A 97: 12513-12518.
9. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, et al. (2000) Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J 19: 5762-5771.
10. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, et al. (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomaviruspositive cancer cells. Oncogene 22: 5938-5945.
11. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68: 3077-3080; discussion 3080.
12. Huibregtse JM, Scheffner M, Howley PM (1993) Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13: 4918-4927.
13. Yamato K, Fen J, Kobuchi H, Nasu Y, Yamada T, et al. (2006) Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther 13: 234-241.
14. Griffin H, Elston R, Jackson D, Ansell K, Coleman M, et al. (2006) Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 355: 360-378.
15. Lagrange M, Boulade-Ladame C, Mailly L, Weiss E, Orfanoudakis G, et al. (2007) Intracellular scFvs against the viral E6 oncoprotein provoke apoptosis in human papillomavirus-positive cancer cells. Biochem Biophys Res Commun 361: 487-492.
16. Cherry JJ, Rietz A, Malinkevich A, Liu Y, Xie M, et al. (2013) Structure based identification and characterization of flavonoids that disrupt human papilloma-virus-16 E6 function. PLoS One 8: e84506.
17. Dymalla S, Scheffner M, Weber E, Sehr P, Lohrey C, et al. (2009) A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein. J Mol Med (Berl) 87: 321-331.
18. Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, et al. (2013) Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science 339: 694-698.
19. Zanier K, ould M'hamed ould Sidi A, Boulade-Ladame C, Rybin V, Chappelle A, et al. (2012) Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.Structure 20: 604-617.
20. Zanier K, Charbonnier S, Baltzinger M, Nomine Y, Altschuh D, et al. (2005)Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance. J Mol Biol 349: 401-412.
21. Schanda P, Brutscher B (2005) Very fast two-dimensional NMR spectroscopy for real-time investigation of dynamic events in proteins on the time scale of seconds. J Am Chem Soc 127: 8014-8015.
22. Butz K, Denk C, Fitscher B, Crnkovic-Mertens I, Ullmann A, et al. (2001) eptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20: 6579-6586.
23. Tomaic V, Pim D, Banks L (2009) The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 393: 7-10.
24. Williamson MP (2013) Using chemical shift perturbation to characterise ligand binding. Prog Nucl Magn Reson Spectrosc 73: 1-16.
25. Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutreix BO (2010) Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov Today 15: 656-667.
26. Zheng X, Gan L, Wang E, Wang J (2013) Pocket-based drug design: exploring pocket space. AAPS J 15: 228-241.
27. Mason JM (2010) Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med Chem 2: 1813-1822.
28. Craik DJ, Fairlie DP, Liras S, Price D (2013) The future of peptide-based drugs. Chem Biol Drug Des 81: 136-147.
29. Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, et al. (2006) Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21: 665-678.
30. Zanier K, Nomine Y, Charbonnier S, Ruhlmann C, Schultz P, et al. (2007) Formation of well-defined soluble aggregates upon fusion to MBP is a generic property of E6 proteins from various human papillomavirus species. Protein Expr Purif 51: 59-70.
31. Keller RLJ (2004) Optimizing the process of nuclear magnetic resonance spectrum analysis and computer aided resonance assignment. Zurich: ETH Zurich.
32. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, et al. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6: 277-293.